Bioocus Medical Group – CAR-T Cell & Gene Therapy in Tianjin, China

Bioocus Medical Group is a China-based cell and gene therapy (CGT) group dedicated to hematologic disease management and precision regenerative medicine. Bioocus operates its own 6,000 m² research center and 3,000 m² GMP manufacturing facility, with dedicated CGT treatment centers at Tianjin Cancer Hospital Airport Campus and Tianjin Perennial Hospital, and has treated more than 1,600 patients from over 50 countries with CAR-T, NK, TIL, and gene therapies since 2016.

Operating within China’s rapidly advancing biomedical ecosystem, Bioocus collaborates with leading hospitals, transplant units, and research institutions to help deliver modern therapies aligned with evolving scientific standards. Its model combines clinical coordination, academic research, and multidisciplinary medical expertise to provide structured treatment solutions for both domestic and international patients.

Mission, Vision & Medical Philosophy

Bioocus aims to bridge the gap between research innovation and real-world patient care by facilitating access to advanced therapies guided by scientific evidence. The organization emphasizes:

• Precision medicine tailored to individual disease profiles
• Integration of cellular engineering and immunotherapy strategies
• Collaboration with leading hematology and oncology specialists
• Continuous development through academic research and clinical trials

Its philosophy centers on delivering patient-focused care supported by innovation, safety protocols, and modern therapeutic design.

Core Medical Specialties

Bioocus is particularly recognized for its involvement in the treatment of complex and rare conditions through advanced therapy programs, including:

Hematologic Oncology

The center focuses on blood-related cancers such as leukemia, lymphoma, and myelodysplastic syndromes. Treatment planning is often multidisciplinary, involving transplant specialists, immunotherapy experts, and hematologists.

Cell and Gene Therapy (CGT)

Bioocus supports next-generation therapeutic models including CAR-T cell therapy coordination, gene-modified cellular treatments, and immune-based therapy strategies designed to target disease at the molecular level.

Stem Cell Transplantation Programs

Patients requiring bone marrow or stem cell transplantation benefit from structured care coordination, pre-treatment assessments, and post-transplant monitoring aligned with international clinical standards.

Regenerative Medicine

In addition to oncology care, the organization explores regenerative applications that use cellular therapy to assist recovery, tissue repair, and immune system modulation.

Our CGT Treatment Centers

Bioocus delivers care through two of Tianjin’s most modern, international-patient-friendly cancer hospitals, both fully equipped for the entire cell therapy journey — leukapheresis, infusion, monitoring, and follow-up.

Tianjin Cancer Hospital Airport Campus

A fully integrated medical city designed around patient comfort, offering GMP-licensed leukapheresis suites and CAR-T infusion rooms built to international standards.

Tianjin Perennial Hospital

Brand-new, fully licensed GMP leukapheresis suites and CAR-T infusion rooms, alongside latest-generation equipment including dual-source PET-CT, TOMO knife, linear accelerators, Y-90 radioembolisation, Lu-177 and Ac-225 radionuclide therapies, NanoKnife irreversible electroporation, and a full interventional oncology suite. A 24/7 intensive care unit is staffed by physicians experienced in managing hundreds of CAR-T cases, with a specific focus on CRS/ICANS prevention and rapid response.

Treatment Programs & Clinical Approach

Bioocus follows a highly personalized clinical pathway designed to adapt therapies to each patient’s condition. The treatment process typically involves:

• Comprehensive medical evaluation and diagnostic review
• Multidisciplinary treatment planning
• Collaboration with specialized transplant or therapy centers
• Continuous monitoring during treatment cycles
• Long-term follow-up strategies to assess recovery and outcomes

Advanced therapies supported through Bioocus may include:

• CAR-T cell therapy for hematologic malignancies
• Allogeneic and autologous stem cell transplantation
• Immunotherapy-based treatment models
• Precision oncology protocols guided by genetic analysis
• Supportive therapies for immune recovery and relapse prevention

Diseases & Cell Therapy Targets Treated

Since 2016, Bioocus has treated patients with hematologic malignancies and solid tumors, achieving strong remission rates through CAR-T, NK, TIL, and gene therapy strategies.

Hematologic Malignancies

• B-Cell Acute Lymphoblastic Leukemia (B-ALL)
• T-Cell Acute Lymphoblastic Leukemia (T-ALL)
• Non-Hodgkin Lymphoma (NHL)
• Multiple Myeloma (MM)
• Acute Myeloid Leukemia (AML)

Solid Tumors

• Neuroblastoma (high-risk/relapsed)
• Brain glioma and brain tumors
• Gastric (stomach) cancer
• Liver cancer (HCC)
• Pancreatic and colorectal cancer

Bioocus’s CAR-T pipeline is built around specific molecular targets matched to each diagnosis, among them CD19 (B-ALL, NHL, AML), CD19+CD20 and CD19+CD22 combinations (NHL, B-ALL), BCMA and GPRC5D (multiple myeloma), CD7 (T-ALL, T-LBL), GD2 and B7H3 (neuroblastoma, brain glioma), GPC3 (liver cancer), and Claudin18.2 (gastric and pancreatic cancer). Beyond CAR-T, the group’s pipeline includes NK cell therapy for solid tumor prevention and recurrence, MSC therapy for aGVHD, TIL therapy for melanoma and other solid cancers, and gene therapy for sickle cell disease and thalassemia.

Research & Academic Contribution

Bioocus maintains strong ties to research initiatives within China’s hematology and biotechnology landscape. Medical teams associated with its network contribute to clinical studies and peer-reviewed publications, helping advance understanding of transplantation outcomes and innovative therapeutic protocols.

Participation in multi-center clinical research reflects the organization’s commitment to scientific progress. Studies involving hematologic malignancies and stem cell transplantation outcomes highlight evolving treatment methods and improved patient prognoses through modern immunotherapy strategies.

Technology & Innovation

The organization integrates advanced technologies to support modern treatment delivery, including:

• High-precision molecular diagnostics
• Cellular engineering and gene modification techniques
• Personalized treatment planning supported by data analytics
• Immune system monitoring and biomarker analysis

By combining research innovation with clinical practice, Bioocus aims to provide access to therapies that represent the future of oncology and regenerative medicine.

Multidisciplinary Medical Team

Bioocus collaborates with experienced hematologists, transplant physicians, oncologists, and research scientists who specialize in advanced therapy development. These experts work together to review complex cases, design treatment pathways, and monitor patient progress throughout the care journey.

The multidisciplinary structure ensures that treatment decisions are supported by diverse medical perspectives, improving safety and optimizing therapeutic outcomes.

International Patient Experience

Bioocus supports global patients seeking advanced treatment options in China by offering structured medical coordination. The approach focuses on transparency, clinical clarity, and patient education.

International patients benefit from:

• Comprehensive medical review prior to travel
• Personalized treatment planning and eligibility evaluation
• Cultural and language support during the medical journey
• Continuous updates regarding treatment progress

The goal is to reduce uncertainty while ensuring patients remain informed and confident throughout their treatment process.

The Universal Medical Travel Role

Universal Medical Travel coordinates the full journey to Bioocus for international patients, working alongside Bioocus’s own four-step patient services process:

• Consultation — secure transfer of medical records for review and a preliminary treatment plan with remote expert assessment
• Admission — visa assistance, flight scheduling, and accommodation arrangements for the patient and accompanying family
• Treatment — airport pickup and coordination of diagnostics and treatment in international-standard wards
• Follow-Up — rehabilitation guidance, long-term monitoring, and telemedicine support after the patient returns home

As with all Universal Medical Travel partners, medical decisions, diagnoses, and treatment plans are made solely by Bioocus’s treating physicians; UMT’s role is coordination, patient advocacy, and logistics.

Patient Outcomes & Clinical Stories

Since 2016, Bioocus has treated more than 1,600 patients from over 50 countries, achieving a maximum overall response rate (ORR) of 90% in hematologic malignancies and 40% long-term survival across its case series. Figures below are drawn from Bioocus’s own published outcome data by indication; individual results vary by patient and disease stage.

For solid tumors, where response is measured primarily through disease control, Bioocus reports disease control rates (DCR) of 88.2% in neuroblastoma, 86.7% in gastric cancer, and 85.7% in liver cancer.

Illustrative case: B-ALL. A 16-year-old male with acute lymphoblastic leukemia underwent CD19/22 CAR-T cell therapy following initial chemotherapy. After an incomplete CAR-T response, he received haploidentical allogeneic stem cell transplantation from his father; bone marrow assessment confirmed complete remission with minimal residual disease negative (MRD-) status, sustained at follow-up.

Illustrative case: Multiple myeloma. A 70-year-old male patient from Egypt with refractory multiple myeloma and extensive skeletal involvement (PET/CT maximum SUV of 17.9) received BCMA-targeted CAR-T therapy. A follow-up PET/CT roughly two months later showed maximum SUV reduced to 5.16, with the patient reporting resolution of bone pain and a return to normal daily activity.

These clinical journeys reflect the organization’s dedication to combining medical expertise with compassionate patient support, emphasizing both scientific advancement and human-centered care.

Why Patients Choose Bioocus

Patients and medical travelers are drawn to Bioocus for several reasons:

• Strong focus on cell and gene therapy innovation
• Collaboration with leading hematology specialists
• Access to modern transplantation techniques
• Integration of research and clinical treatment
• Personalized care planning supported by multidisciplinary expertise

The organization’s commitment to advanced medicine positions it as a specialized destination for patients exploring next-generation therapies.